The medical device industry is making a strategic push to reshape CMS's proposed RAPID (Reasonable Assured Pathway for Innovative Devices) initiative before it becomes finalized policy. AdvaMed, the leading trade association representing medtech manufacturers, is advocating for significant expansion of which products qualify for expedited review—a move that could fundamentally alter how breakthrough technologies reach patients and which vendors gain competitive advantages in the market.
The current iteration of CMS's RAPID pathway, while promising faster reimbursement decisions, appears narrowly tailored to a specific category of devices. AdvaMed's campaign to broaden eligible product categories, particularly by including diagnostic technologies, reflects a growing tension in healthcare innovation policy: how aggressive should regulators and payers be in fast-tracking technologies, and who decides which innovations warrant expedited treatment?
What's Really at Stake
For health system leaders and procurement teams, the scope of the RAPID pathway carries direct operational implications. A narrowly defined program means limited access to expedited coverage decisions, forcing administrators to navigate traditional, often lengthy national coverage determination (NCD) processes. Broader eligibility would theoretically democratize access to faster market entry for more vendors, potentially increasing competitive options available to hospital networks.
However, the real strategic importance lies in what AdvaMed is simultaneously requesting: predictable timelines for national coverage determinations. This demand addresses a chronic pain point in healthcare technology adoption. Currently, the uncertainty around NCD completion dates creates planning challenges for health systems and financial unpredictability for vendors. Establishing set timelines—even if lengthy—would allow both parties to make more informed decisions about implementation, workforce training, and capital allocation.
Diagnostic technology inclusion is particularly significant. Diagnostics represent a growing portion of medical innovation and often serve as gatekeepers for downstream treatment decisions. If diagnostics remain excluded from expedited pathways while therapeutics receive preferential treatment, it could create misaligned incentives in the healthcare ecosystem, where testing capabilities lag behind treatment options.
For vendors, especially mid-market and smaller medtech companies, pathway eligibility becomes a crucial competitive factor. Breakthrough designation and expedited review can mean the difference between capturing early market share and watching larger competitors dominate adoption cycles. The broader the eligibility criteria, the more vendors have realistic pathways to accelerated reimbursement consideration.
The medtech industry's timing is strategic. By advocating for expansion now, before RAPID becomes institutionalized policy, AdvaMed is attempting to shape a program during its formative stages rather than fighting for changes years into implementation. CMS will need to balance genuine innovation incentives against the risks of creating a two-tiered system where certain product categories receive preferential treatment.
Health system leaders should monitor these policy negotiations closely. The final RAPID framework will influence which technologies receive favorable reimbursement consideration and how quickly they'll navigate the coverage determination process. If the pathway expands significantly, expect increased vendor competition for RAPID eligibility designation, potentially benefiting health systems through more innovation options. Conversely, if CMS resists expansion, traditional procurement dynamics will persist, with established players potentially maintaining advantages.
The broader question underlying this debate concerns innovation governance itself: Should payers prioritize speed-to-market for all breakthrough technologies, or maintain more selective criteria? How that question is answered will reshape healthcare technology adoption patterns for years to come.
Reporting basis: medtechdive.com. Analysis by the HTC editorial desk.